A pan-positive allosteric modulator that mediates sustainable GPCR activation
Sun, Q.; He, G.; Xu, X.; Kong, F.; Zhang, S.; Sun, X.; Yan, C.; Liu, X.
Show abstract
Approximately 1/3 of all clinical drugs exert their therapeutic effects by modulating the activity of G protein-coupled receptors (GPCRs). Thus, there is a constant interest in finding novel ways to modulate GPCR activity. In this work, through a newly established Survival Pressure Selection (SPS) method for high-throughput screening of GPCR agonists, we discover that atazanavir functions as an agonist for GPR119. Further studies suggest that atazanavir is capable of activating a number of Family A GPCRs, including the {beta}1 adrenergic receptor ({beta}1AR), the {beta}2 adrenergic receptor ({beta}2AR) and the opoioid receptor (OR). Cryo-EM structures reveal that atazanavir binds to an allosteric pocket near TM6/7 in both GPR119 and the {beta}1AR. Pharmacological studies suggest that atazanavir mediates non-canonical signaling of Family A GPCRs. During this process, G protein and {beta}-arrestin are spatially close, but {beta}-arrestin forms a complex with the receptor and G protein instead of desensitizing G protein signaling, thus resulting in sustained G protein signaling. The work expands the signal transduction modes and pharmacological properties of allosteric modulators for GPCRs and provides a general starting point for developing therapeutics targeting this allosteric site.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.